Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab

NCT04701476 is registered in ClinicalTrials.gov with Teclison Ltd. as lead sponsor.

NCT NCT04701476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04701476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab
Lead sponsor
Teclison Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
May 20, 2021
Completion date
September 30, 2027
Enrollment
110 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer; lung cancer